-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QyU/6E0nEoSdjAf3H9T49cnN3d/I725qIeDISPR+J1m9jBHUTo/U4GWA8VDtgUHN mHRAu0h2cAXcfnW3h4mXXw== 0000922423-98-001227.txt : 19981110 0000922423-98-001227.hdr.sgml : 19981110 ACCESSION NUMBER: 0000922423-98-001227 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19981109 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: COLUMBIA LABORATORIES INC CENTRAL INDEX KEY: 0000821995 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 592758596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-40470 FILM NUMBER: 98741107 BUSINESS ADDRESS: STREET 1: 2665 S BAYSHORE DR PH 11-B CITY: MIAMI STATE: FL ZIP: 33133 BUSINESS PHONE: 305-860-16 MAIL ADDRESS: STREET 1: 2665 SOUTH BAYSHORE DRIVE PH 11-B CITY: MIAMI STATE: FL ZIP: 33133 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: APOSTOLAKIS JAMES J CENTRAL INDEX KEY: 0001066096 STANDARD INDUSTRIAL CLASSIFICATION: [] FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O LEXINGTON SHIPPING & TRADING CORP STREET 2: 950 3RD AVE CITY: NEW YORK STATE: NY ZIP: 10022 MAIL ADDRESS: STREET 1: C/O LEXINGTON SHIPPING & TRADING CORP STREET 2: 950 3RD AVE CITY: NEW YORK STATE: NY ZIP: 10022 SC 13D/A 1 AMENDMENT NO 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Columbia Laboratories, Inc. --------------------------- (Name of Issuer) Common Stock, $.01 par value ---------------------------- (Title of Class of Securities) 197779101 --------- (CUSIP Number) James J. Apostolakis c/o Lexington Shipping and Trading Corp. 950 Third Avenue, 27th Floor New York, New York 10022 (212) 588-1900 -------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 4, 1998 ---------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box: |_|
SCHEDULE 13D CUSIP No. 197779101 - ------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON James J. Apostolakis - ------------------------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)|X| * (b)|_| * Disclaimed - ------------------------------------------------------------------------------------------------- 3) SEC USE ONLY - ------------------------------------------------------------------------------------------------- 4) SOURCE OF FUNDS PF,WC - ------------------------------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - ------------------------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------------------------- 7) SOLE VOTING POWER 926,000 (See Item 5) NUMBER ------------------------------------------------------------------------ OF 8) SHARED VOTING POWER SHARES Not Applicable BENEFICIALLY ------------------------------------------------------------------------ OWNED BY 9) SOLE DISPOSITIVE POWER EACH 926,000 (See Item 5) REPORTING ------------------------------------------------------------------------ PERSON 10) SHARED DISPOSITIVE POWER WITH Not Applicable - ------------------------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 926,000 (See Item 5) - ------------------------------------------------------------------------------------------------- 12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |_| - ------------------------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.2 % - ------------------------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON IN - ------------------------------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 197779101 - ------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON David Ray - ------------------------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)|X| * (b)|_| *Disclaimed - ------------------------------------------------------------------------------------------------- 3) SEC USE ONLY - ------------------------------------------------------------------------------------------------- 4) SOURCE OF FUNDS PF - ------------------------------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - ------------------------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------------------------- 7) SOLE VOTING POWER 214,000 NUMBER ------------------------------------------------------------------------ OF 8) SHARED VOTING POWER SHARES Not Applicable BENEFICIALLY ------------------------------------------------------------------------ OWNED BY 9) SOLE DISPOSITIVE POWER EACH 214,000 REPORTING ------------------------------------------------------------------------ PERSON 10) SHARED DISPOSITIVE POWER WITH Not Applicable - ------------------------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 214,000 - ------------------------------------------------------------------------------------------------- 12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |_| - ------------------------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.7 % - ------------------------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON IN - ------------------------------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 197779101 - ------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bernard Marden - ------------------------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)|X| * (b)|_| *Disclaimed - ------------------------------------------------------------------------------------------------- 3) SEC USE ONLY - ------------------------------------------------------------------------------------------------- 4) SOURCE OF FUNDS PF - ------------------------------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - ------------------------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------------------------- 7) SOLE VOTING POWER 473,700 NUMBER ------------------------------------------------------------------------ OF 8) SHARED VOTING POWER SHARES Not Applicable BENEFICIALLY ------------------------------------------------------------------------ OWNED BY 9) SOLE DISPOSITIVE POWER EACH 473,700 REPORTING ------------------------------------------------------------------------ PERSON 10) SHARED DISPOSITIVE POWER WITH Not Applicable - ------------------------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 473,700 - ------------------------------------------------------------------------------------------------- 12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |_| - ------------------------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.7 % - ------------------------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON IN - ------------------------------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 197779101 - ------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Christopher Castroviejo - ------------------------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)|X| * (b)|_| *Disclaimed - ------------------------------------------------------------------------------------------------- 3) SEC USE ONLY - ------------------------------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC - ------------------------------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - ------------------------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------------------------- 7) SOLE VOTING POWER 0 (See Item 5) NUMBER ------------------------------------------------------------------------ OF 8) SHARED VOTING POWER SHARES Not Applicable BENEFICIALLY ------------------------------------------------------------------------ OWNED BY 9) SOLE DISPOSITIVE POWER EACH 0 (See Item 5) REPORTING ------------------------------------------------------------------------ PERSON 10) SHARED DISPOSITIVE POWER WITH Not Applicable - ------------------------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 (See Item 5) - ------------------------------------------------------------------------------------------------- 12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |_| - ------------------------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0 % - ------------------------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------------------------
Schedule 13D ------------ Item 1 of the Schedule 13D, "Security and Issuer," is amended and restated in its entirety as follows: This Statement amends the Schedule 13D dated July 16, 1998, as amended by Amendment No. 1 filed on July 23, 1998 and by Amendment No. 2 filed on October 6, 1998 (the "Schedule 13D"), filed by James J. Apostolakis and the other Reporting Persons named therein relating to the Common Stock, $.01 par value (the "Common Stock"), of Columbia Laboratories, Inc., a Delaware corporation (the "Company"). Notwithstanding this Amendment No. 3, the Schedule 13D speaks as of this date. Capitalized terms used herein without definition have the meanings assigned to them in the Schedule 13D, except for "Reporting Persons," as explained below. In each case, the filing of the Schedule 13D and Amendments thereto does not constitute an admission that the Reporting Persons constitute a "group" for purposes of the Securities Exchange Act of 1934, as amended, or the rules promulgated thereunder or for any other purpose whatsoever. Each of the Reporting Persons expressly disclaims beneficial ownership of any Common Stock beneficially owned by any of the other Reporting Persons or any other person. Although included in the prior Schedule 13D filing, Anthony R. Campbell will file a separate Schedule 13D which reflects his beneficial ownership and the beneficial ownership of the Campbell Entities of Common Shares. All references to the "Reporting Persons" shall include all of the previous persons filing this Schedule 13D except for Mr. Campbell. Item 2 (a) - (c) of the Schedule 13D, "Identity and Background," is amended to amend and restate the second paragraph thereof in its entirety as follows: An aggregate of 4,315,100 shares of common stock, representing approximately 15% of the shares of outstanding Common Stock, were beneficially owned by the various Reporting Persons included in this Schedule 13D together with Mr. Anthony R. Campbell (who has filed a separate schedule 13D) and Mr. David Knott (who has filed a separate Schedule 13D), as of November 4, 1998. Item 3 of the Schedule 13D, "Source and Amount of Funds or other Consideration," is amended to amend and restate the first sentence thereof in its entirety as follows: As of November 4, 1998, the various Reporting Persons beneficially owned an aggregate of 1,613,700 shares of Common Stock, all of which were acquired on the open market over the course of time at then-current prices for an aggregate consideration of approximately $32,845,499. Items 5 (a) and (c) of the Schedule 13D, "Interest in Securities of the Issuer," are amended and restated in their entirety as follows: (a) An aggregate of 4,315,100 shares of Common Stock, representing approximately 15% of the shares of outstanding Common Stock, were beneficially owned by the various Reporting Persons included in this Schedule 13D together with Mr. Anthony R. Campbell (who has filed a separate Schedule 13D) and Mr. David Knott (who has filed a separate Schedule 13D), as of November 4, 1998. The various Reporting Persons included in this Schedule 13D beneficially own an aggregate of 1,613,700 shares of Common Stock, representing approximately 5.6% of the shares of outstanding Common Stock.1 An additional 1,240,300 shares of Common Stock, representing an additional approximately 4.3% of the shares of the outstanding Common Stock, were beneficially owned by David Knott as of November 4, 1998 including 1,155,500 shares reported in a Schedule 13D separately filed and an aggregate of 84,800 shares of Common Stock purchased since that filing. An additional 1,461,100 shares of Common Stock, representing an additional approximately 5.1% of the shares of outstanding Common Stock, were beneficially owned by Anthony R. Campbell as of November 4, 1998, reported in a Schedule 13D separately filed. The following table sets forth the number of shares of Common Stock beneficially owned by each of the Reporting Persons as of November 4, 1998 and the percentage of the outstanding Common Stock such ownership represents. Item 2 sets forth the entities which own Common Stock of which Mr. Apostolakis or Mr. Castroviejo may be deemed beneficial owners. Percentage of Reporting Shares of Outstanding Person Common Stock Common Stock - ------ ------------ ------------ Mr. Apostolakis 926,0002/2/ 3.2 Mr. Ray 214,000 0.7 - ------------------------------ /1/ Based upon 28,684,687 shares of Common Stock reported by the Company to be outstanding as of July 31, 1998. /2/ Not including certain non-qualified options, not presently exercisable, to purchase 50,000 shares at a price of $11.625 granted on February 2, 1998. Mr. Marden 473,700 1.7 Mr. Castroviejo/3/ 0 0 The following table sets forth the number of shares of Common Stock owned by the Apostolakis Entities as of November 4, 1998. Percentage of Apostolakis Shares of Outstanding Entity Common Stock Common Stock - ------ ------------ ------------ Lexington Corp. 68,500 0.2 Bradmar Corp. 57,850 0.2 Bradford Inc. 42,500 0.1 Pension Plans 17,625 0.06 Additionally, Mr. Apostolakis individually owns 739,525 shares of Common Stock, representing approximately 2.6% of the outstanding Common Stock. The following table sets forth the number of shares of Common Stock owned by the Castroviejo Entities as of November 4, 19984. Percentage of Castroviejo Shares of Outstanding Entity Common Stock Common Stock - ------ ------------ ------------ International Parallax 0 0 Parallax LP 0 0 Mr. Castroviejo and the Castroviejo Entities no longer hold any shares of Common Stock as of November 4, 1998. Each of the Reporting Persons expressly disclaims beneficial ownership of any Common Stock beneficially owned by any of the other Reporting Persons or any other person. - ------------------------------- /3/ Through his position as a general partner of TC Management, the sole general partner of Windsor LP, Mr. Castroviejo may also be deemed to beneficially own shares of Common Stock, owned by Windsor LP, as to which he disclaims beneficial ownership. The above table reflects only Mr. Castroviejo's position as president of the manager of International Parallax and general partner of Parallax LP. (see Item 2). /4/ Formerly International Parallax owned 15,000 shares of Common Stock, representing approximately .05% of the outstanding Common Stock, and Parallax LP owned 315,000 shares of Common Stock, representing approximately 1.1% of the outstanding Common Stock. The shares held by International Parallax and Parallax LP were inadvertently interchanged in Schedule 13D/A Amendment No. 1. (c) Except as set forth on Schedule I annexed hereto, the Reporting Persons, Apostolakis Entities and Castroviejo Entities have not effected any transactions in the Common Stock during the past 60 days. All such transactions were effected in the open market. Item 6 of Schedule 13D, "Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer," is amended and restated in its entirety as follows: Notwithstanding certain discussions with the Company's management, there is no present understanding between the Reporting Person and the Company. Except as disclosed herein in connection with certain contacts with the Company's senior management and related matters, there are no contracts, arrangements, understandings or relationships required to be disclosed herein with respect to the Company's securities between each of the Reporting Persons and each of Messrs. Campbell or Knott. (See Item 4.) SIGNATURES ---------- After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certify that the information set forth in this Statement is true, complete and correct. Dated: November 9, 1998 /s/ James J. Apostolakis ------------------------ Name: James J. Apostolakis /s/ David Ray ------------- Name: David Ray /s/ Bernard Marden ------------------ Name: Bernard Marden /s/ Christopher Castroviejo --------------------------- Christopher Castroviejo SCHEDULE I IS AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS: SCHEDULE I TRANSACTIONS IN COMMON STOCK OF COLUMBIA LABORATORIES, INC. DURING THE PRECEDING 60 DAYS Shares Purchased by James J. Apostolakis: Number of Shares Date Purchased Total Cost - ---- --------- ---------- 9/28/98 2,000 $7,750 10/1/98 2,000 6,750 10/2/98 3,000 9,180 10/5/98 6,000 17,625 10/6/98 6,300 17,325 10/7/98 4,000 12,215 10/8/98 7,000 18,730 10/9/98 7,000 18,730 10/12/98 2,000 5,428 10/13/98 2,200 5,574.50 10/15/98 4,000 10,955 10/20/98 6,000 21,055 10/21/98 3,400 12,225 10/26/98 10,000 38,755 10/27/98 5,000 18,317.50 10/28/98 8,000 26,4678.50 10/29/98 15,000 48,880 11/2/98 8,000 29,360 Shares Purchased by Bradford Inc.: Number of Shares Date Purchased Total Cost - ---- --------- ---------- 10/7/98 1,000 $3,065 10/12/98 1,000 2,752.50 10/15/98 2,000 5,500 10/20/98 2,000 7,375 10/27/98 1,000 3,752.50 10/29/98 1,500 4,950 Shares Purchased by Lexington Corp.: Number of Shares Date Purchased Total Cost - ---- --------- ---------- 10/1/98 2,000 $6,750 10/2/98 1,000 3,060 10/5/98 1,000 2,937.50 10/6/98 2,400 6,900 10/12/98 1,000 2,752.50 10/13/98 1,000 2,565 10/15/98 2,000 5,500 10/20/98 3,000 11,217.50 10/21/98 1,000 3,627.50 10/26/98 2,000 7,375.50 10/27/98 2,000 7,500 10/28/98 2,000 6,875 10/29/98 4,000 13,205 11/2/98 2,500 9,500 Shares Sold by Parallax LP: Number of Shares Date Sold Total Cost - ---- ---------- ---------- 9/8/98 30,000 $116,546 Shares Sold by International Parallax: Number of Shares Date Sold Total Cost - ---- --------- ----------- 9/23/98 10,000 $40,099 Shares Purchased by Mr. Ray: Number of Shares Date Purchased Total Cost - ---- --------- ---------- 10/9/98 1,000 $2,750 10/26/98 24,100 85,600 10/27/98 3,900 13,650 Shares Purchased by Mr. Marden: Number of Shares Date Purchased Total Cost - ---- --------- ---------- 10/16/98 50,000 $150,000 -----END PRIVACY-ENHANCED MESSAGE-----